The objective of this review is to describe the incidence and severity of drug-induced ILD across currently approved and investigational anti-HER2 therapies in female patients with metastatic breast cancer (MBC), and describe recommendations for monitoring and management of anti-HER2 drug-induced ILD among MBC patients. This evidence concerns the gene ERBB2 and interstitial lung disease.